Biblio

Found 186 results
Author Keyword Title Type [ Year(Asc)]
Filters: First Letter Of Keyword is F  [Clear All Filters]
2016
J. A. Ledermann, Embleton, A. C., Raja, F., Perren, T. J., Jayson, G. C., Rustin, G. J. S., Kaye, S. B., Hirte, H., Eisenhauer, E., Vaughan, M., Friedlander, M. Leonard, Gonzalez-Martin, A., Stark, D., Clark, E., Farrelly, L., Swart, A. Marie, Cook, A. D., Kaplan, R. S., and Parmar, M. K. B., Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial., Lancet, vol. 387, no. 10023, pp. 1066-74, 2016.
D. J. Pulford, Harter, P., Floquet, A., Barrett, C., Suh, D. Hoon, Friedlander, M. Leonard, Arranz, J. Angel, Hasegawa, K., Tada, H., Vuylsteke, P., Mirza, M. R., Donadello, N., Scambia, G., Johnson, T., Cox, C., Chan, J. K., Imhof, M., Herzog, T. J., Calvert, P., Wimberger, P., Berton-Rigaud, D., Lim, M. Cheol, Elser, G., Xu, C. - F., and Bois, Adu, Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study., BMC Med Ethics, vol. 17, no. 1, p. 63, 2016.
A. M. Angarita, Johnson, C. Alonia Lil, Fader, A. Nickles, and Christianson, M. S., Fertility preservation: A key survivorship issue for young women with cancer , Frontiers in Oncology , vol. 6, no. 102, 2016.
A. M. Angarita, Johnson, C. Alonia Lil, Fader, A. Nickles, and Christianson, M. S., Fertility preservation: A key survivorship issue for young women with cancer , Frontiers in Oncology , vol. 6, no. 102, 2016.
A. du Bois, Kristensen, G. B., Ray-Coquard, I., Reuss, A., Pignata, S., Colombo, N., Denison, U., Vergote, I. B., Del Campo, J. M., Ottevanger, P., Heubner, M., Minarik, T., Sevin, E., de Gregorio, N., Bidziński, M., Pfisterer, J., Malander, S., Hilpert, F., Mirza, M. R., Scambia, G., Meier, W., Nicoletto, M. O., Bjørge, L., Lortholary, A., Sailer, M. Oliver, Merger, M., and Harter, P., Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial., Lancet Oncol, vol. 17, no. 1, p. 89, 2016.
J. K. Chan, Brady, M. F., Penson, R. T., Huang, H., Birrer, M. J., Walker, J. L., DiSilvestro, P. A., Rubin, S. C., Martin, L. P., Davidson, S. A., Huh, W. K., O'Malley, D. M., Boente, M. P., Michael, H., and Monk, B. J., Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer., N Engl J Med, vol. 374, no. 8, p. 748, 2016.
2015
A. M. Poveda, Selle, F., Hilpert, F., Reuss, A., Savarese, A., Vergote, I. B., Witteveen, P., Bamias, A., Scotto, N., Mitchell, L., and Pujade-Lauraine, E., Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial., J Clin Oncol, vol. 33, no. 32, p. 3838, 2015.
R. T. Penson, Huang, H. Q., Wenzel, L. B., Monk, B. J., Stockman, S., Long, H. J., Ramondetta, L. M., Landrum, L. M., Oaknin, A., Reid, T. J. A., Leitao, M. M., Method, M., Michael, H., and Tewari, K. S., Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240)., Lancet Oncol, vol. 16, no. 3, pp. 301-11, 2015.
S. Mahner, Meier, W., du Bois, A., Brown, C., Lorusso, D., Dell'Anna, T., Cretin, J., Havsteen, H., Bessette, P., Zeimet, A. G., Vergote, I. B., Vasey, P. A., Pujade-Lauraine, E., Gladieff, L., and Ferrero, A., Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial., Eur J Cancer, vol. 51, no. 3, pp. 352-8, 2015.
D. K. Gaffney, Suneja, G., Ryu, S. Young, McCormick, M., Plante, M., Mileshkin, L. R., Small, W., Bacon, M., Stuart, G. C. E., and Kitchener, H. C., The Cervix Cancer Research Network: A Global Outreach Effort on Behalf of the Gynecologic Cancer InterGroup., Int J Radiat Oncol Biol Phys, vol. 92, no. 3, pp. 506-8, 2015.
C. Khoon Lee, Lord, S., Grunewald, T., Gebski, V., Hardy-Bessard, A. - C., Sehouli, J., Woie, K., Heywood, M., Schauer, C., Vergote, I. B., Scambia, G., Ferrero, A., Harter, P., Pujade-Lauraine, E., and Friedlander, M. Leonard, Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial., Gynecol Oncol, vol. 136, no. 1, pp. 18-24, 2015.
A. Floquet, Vergote, I. B., Colombo, N., Fiane, B., Monk, B. J., Reinthaller, A., Calvert, P., Herzog, T. J., Meier, W., Kim, J. - W., Del Campo, J. M., Friedlander, M. Leonard, Pisano, C., Isonishi, S., Crescenzo, R. J., Barrett, C., Wang, K., Mitrica, I., and du Bois, A., Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial., Gynecol Oncol, vol. 136, no. 1, p. 42, 2015.
A. Floquet, Vergote, I. B., Colombo, N., Fiane, B., Monk, B. J., Reinthaller, A., Calvert, P., Herzog, T. J., Meier, W., Kim, J. - W., Del Campo, J. M., Friedlander, M. Leonard, Pisano, C., Isonishi, S., Crescenzo, R. J., Barrett, C., Wang, K., Mitrica, I., and du Bois, A., Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial., Gynecol Oncol, vol. 136, no. 1, p. 42, 2015.
A. M. Oza, Cook, A. D., Pfisterer, J., Embleton, A. C., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G. B., Carey, M. S., Beale, P., Cervantes, A., Park-Simon, T. - W., Rustin, G. J. S., Joly, F., Mirza, M. R., Plante, M., Quinn, M., Poveda, A. M., Jayson, G. C., Stark, D., Swart, A. Marie, Farrelly, L., Kaplan, R. S., Parmar, M. K. B., and Perren, T. J., Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial., Lancet Oncol, vol. 16, no. 8, p. 936, 2015.
2014
E. Pujade-Lauraine, Hilpert, F., Weber, B., Reuss, A., Poveda, A. M., Kristensen, G. B., Sorio, R., Vergote, I. B., Witteveen, P., Bamias, A., Pereira, D., Wimberger, P., Oaknin, A., Mirza, M. Raza, Follana, P., Bollag, D., and Ray-Coquard, I., Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial., J Clin Oncol, vol. 32, no. 13, p. 1308, 2014.
N. Simon Reed, Gomez-Garcia, E., Gallardo-Rincon, D., Barrette, B. A., Baumann, K. H., Friedlander, M. Leonard, Kichenadasse, G., Kim, J. - W., Lorusso, D., Mirza, M. Raza, and Ray-Coquard, I., Gynecologic Cancer InterGroup (GCIG) consensus review for carcinoid tumors of the ovary., Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S35-41, 2014.
H. Fujiwara, Yokota, H., Monk, B. J., Treilleux, I., Devouassoux-Shisheboran, M., Davis, A., Kim, J. - W., Mahner, S., Stany, M., Pignata, S., Ray-Coquard, I., and Fujiwara, K., Gynecologic Cancer InterGroup (GCIG) consensus review for cervical adenocarcinoma., Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S96-101, 2014.
A. Okamoto, Glasspool, R. M., Mabuchi, S., Matsumura, N., Nomura, H., Itamochi, H., Takano, M., Takano, T., Susumu, N., Aoki, D., Konishi, I., Covens, A., Ledermann, J. A., Mezzanzanica, D., Mezzazanica, D., Steer, C., Millan, D., McNeish, I. A., Pfisterer, J., Kang, S., Gladieff, L., Bryce, J., and Oza, A. M., Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary., Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S20-5, 2014.
K. Hasegawa, Nagao, S., Yasuda, M., Millan, D., Viswanathan, A., Glasspool, R. M., Devouassoux-Shisheboran, M., Covens, A., Lorusso, D., Kurzeder, C., Kim, J. - W., Gladieff, L., Bryce, J., Friedlander, M. Leonard, and Fujiwara, K., Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix., Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S90-5, 2014.
F. Amant, Floquet, A., Friedlander, M. Leonard, Kristensen, G. B., Mahner, S., Nam, E. Ji, Powell, M. A., Ray-Coquard, I., Siddiqui, N. Ahmad, Sykes, P., Westermann, A. M., and Seddon, B., Gynecologic Cancer InterGroup (GCIG) consensus review for endometrial stromal sarcoma., Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S67-72, 2014.
P. Pautier, Nam, E. Ji, Provencher, D. M., Hamilton, A. L., Mangili, G., Siddiqui, N. Ahmad, Westermann, A. M., Reed, N. Simon, Harter, P., and Ray-Coquard, I., Gynecologic Cancer InterGroup (GCIG) consensus review for high-grade undifferentiated sarcomas of the uterus., Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S73-7, 2014.
J. A. Ledermann, Luvero, D., Shafer, A., O'Connor, D., Mangili, G., Friedlander, M. Leonard, Pfisterer, J., Mirza, M. R., Kim, J. - W., Alexandre, J., Oza, A. M., and Brown, J., Gynecologic Cancer InterGroup (GCIG) consensus review for mucinous ovarian carcinoma., Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S14-9, 2014.
M. Leonard Friedlander, Covens, A., Glasspool, R. M., Hilpert, F., Kristensen, G. B., Kwon, S., Selle, F., Small, W., Witteveen, E., and Russell, P., Gynecologic Cancer InterGroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract., Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S78-82, 2014.
P. Harter, Gershenson, D., Lhomme, C., Lecuru, F., Ledermann, J. A., Provencher, D. M., Mezzanzanica, D., Quinn, M., Maenpaa, J. U., Kim, J. - W., Mahner, S., Hilpert, F., Baumann, K. H., Pfisterer, J., and du Bois, A., Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors)., Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S5-8, 2014.
C. Gourley, Farley, J., Provencher, D. M., Pignata, S., Mileshkin, L. R., Harter, P., Maenpaa, J. U., Kim, J. - W., Pujade-Lauraine, E., Glasspool, R. M., Ray-Coquard, I., and Gershenson, D., Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas., Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S9-13, 2014.

Pages